The Connecticut Business & Industry Association is the voice of business in Connecticut, with thousands of member companies championing change at the State Capitol, shaping debate about economic competitiveness, and fighting for a better future for all.
The Connecticut Bioscience Growth Council consists of representatives from CBIA member companies with biotech, pharmaceutical, and bioscience-related interests.
It was organized to better address the issues affecting this growing sector, especially the importance of strong intellectual property protection and the industry's uniquely high R&D costs.
Working with CBIA staff, the council communicates to policymakers strategies to fuel industry job growth and timely introduction of new medicines, medical devices, and products developed and/or manufactured with the aid of bioscience.
The council will represent the interests of biotech and biopharma companies—large and small—at the State Capitol and regulatory agencies, providing greater advocacy support and resources, and developing an overall plan for better positioning these companies at the state, regional, and national level.
Council members meet regularly and interacts with the Connecticut General Assembly's Life Sciences Caucus and Connecticut's Congressional delegation.
The council is led by CBIA's Paul Pescatello.
As part of the council's advocacy efforts, Pescatello works to enhance and secure important policies, such as the research and development tax credit for both established and early-stage companies.
In addition to representing the biotech and biopharma industries at the state level, Pescatello serves as president of the New England Biotech Association, chairs We Work for Health Connecticut, and works closely with the Biotechnology Industry Organization.
Curing disease. Growing healthier, more sustainable crops. Adapting energy and environmental needs while moderating demands on our changing world. These…
Amid the many bills state legislators are considering this General Assembly session, perhaps the most consequential is SB 539, which…
It’s not surprising how many biopharma bills were introduced this legislative session, considering the state’s bioscience investments, and that healthcare…
The state’s bioscience sector got a big boost this week when health information company Sema4 announced plans to move its…
It’s not difficult to see why Connecticut’s bioscience sector has a great deal of support in the General Assembly. Bioscience…
Connecticut’s Healthcare Cabinet has issued a series of policy recommendations designed to address prescription drug costs. Among them is establishing…